Ovid and Takeda's epilepsy drug gets new life at Perceptive-backed NewCo

PartnershipPositive

AI Analysis

Summary

An epilepsy treatment candidate that failed two Phase 3 trials approximately 26 months ago has been acquired by a Perceptive Advisors-backed NewCo for continued development, representing a repositioning effort for the failed asset.

Clinical Trial Data

Phase

Phase_3

Primary Endpoint

Not Met

Outcome Details

Failed Phase 3 trials ~26 months ago; drug acquired by Perceptive-backed NewCo for development continuation

Importance:5/10

Sentiment:

0.30

epilepsyPhase 3 failureasset acquisitiondrug repositioningTakedaPerceptive Advisors

Related Companies

$TAK

Read the original article

Published by Endpoints News on August 13, 2026 6:31 PM

Read Original